Control Group Outcomes in Trials of Psilocybin, SSRIs, or Esketamine for Depression: A Meta-Analysis.
Hieronymus F, López E, Werin Sjögren H, Lundberg J
Publication record · Explore literaturePublic tracker catalogue and stored structured reference metadata. External references may have identifiers only. No live external citation lookup is performed.
References — this paper cites (0)
No references identified in the available metadata. This does not establish that none exist.
Cited by — these papers cite this paper (9)
- Efficacy and safety of psilocybin-assisted therapy for alcohol use disorder: A systematic review and meta-analysis 2026-10-08 · Expand citations
- Caution before canonisation: a clinical and implementation science perspective on psychedelics 2026-10-05 · Expand citations
- Placebo, Psilocybin und der vermaledeite p-Wert 2026-10-01 · Expand citations
- PSILOCYBIN IN THE TREATMENT OF DEPRESSIVE DISORDERS: CLINICAL EVIDENCE AND ITS POTENTIAL TO ADDRESS THE GLOBAL MENTAL HEALTH CRISIS - A REVIEW 2026-06-24 · Expand citations
- Short-Term and Late-Term Effects of Psilocybin on Symptoms in Major Depression 2026-05-15 · Expand citations
- Psilocybin in the Treatment of Cocaine Use Disorder 2026-05-07 · Expand citations
- Efficacy and Safety of Psilocybin in Treatment-Resistant Major Depression 2026-05-01 · Expand citations
- A living systematic review, meta-analysis and open-data resource of randomized controlled trials of psilocybin treatment for symptoms of depression 2026-04-06 · Expand citations
- With great power comes great responsibility: Promise and caution in the new psychedelic renaissance 2025-09-23 · Expand citations